NasdaqGS:SNDXBiotechs
Syndax Pharmaceuticals (SNDX) Narrows Q1 Loss To US$42.7 Million Challenging Bearish Narratives
Syndax Pharmaceuticals (SNDX) opened Q1 2026 with total revenue of US$64.9 million and a basic EPS loss of US$0.48, alongside a net loss of US$42.7 million. This puts fresh numbers around how the business is scaling its commercial model while still running in the red. Over recent quarters the company has reported revenue of US$7.7 million in Q4 2024, US$20.0 million in Q1 2025, and US$68.7 million in Q4 2025, with basic EPS losses of US$1.10, US$0.98, and US$0.78 over those same periods as it...